JPRN-jRCT2032230521尚未招募Unknown
Multicenter, Randomized, Open-label Study of Diabetes Treatment Support System (BAP0527 and Blood Glucose Meter) in Patients with Type 2 Diabetes Mellitus
Yamada Emi0 个研究点目标入组 240 人开始时间: 2023年12月20日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Participant has been diagnosed with type 2 diabetes for at least 12 weeks (84 days) at visit 1.
- •2. Participant being treated with diet and exercise therapy alone or hypoglycemic medications other than insulin in addition to diet and exercise therapy, who have been on the same therapy for at least 12 weeks (84 days) at visit 1.
- •3. Participant is considered to have room for improvement in diabetes self-management, including the conduct of diet and exercise therapy, and is willing to improve their diabetes self-management in compliance with the requirements for use of BAP0527 and blood glucose meter (visit 1).
- •4. Participant is considered to be manageable outpatiently during the study participation (visit 1).
- •5. Participant has no problem with cognitive function, visual acuity and ability to operate devices in entering data to BAP0527 and using a blood glucose meter (visit 1).
- •6. Participant who has a smartphone device and have been using it continuously at visit 1. The device must meet the following operating system requirements:
- •- iOS: version 13 and above
- •- Android: version 10 and above
- •7. Participant with HbA1c (central lab measurement) 8.0 percentage to 10.0 percentage at visit 1.
- •8. Participant who meets inclusion criteria 2-6 also at visit 2.
- •9. Female participants:
- •o Female participant is eligible to participate if she is not pregnant and one of the following conditions applies:
- •- Not a Women of Childbearing Potential (WOCBP)
- •- A WOCBP who has a negative urine or serum pregnancy test from the time of informed consent to visit 2 and agrees to follow the contraceptive guidance from the time of informed consent to the end of the follow-up period.
- •o Female participant must agree not to breastfeed from the time of informed consent to the end of the follow-up period.
- •10. Participant agrees not to participate in another interventional study while participating in this study.
排除标准
- •1. Participant has been diagnosed with diabetes other than type 2 diabetes, such as type 1 diabetes and secondary diabetes.
- •2. Participant with a history of or undergoing treatment for diabetic ketoacidosis.
- •3. Participant with diabetic proliferative retinopathy (except for those who have undergone photocoagulation and whose symptoms are stable).
- •4. Participant has been diagnosed with clinically significant cardiovascular or cerebrovascular diseases within 12 weeks (84 days) prior to visit 1 (including the day of visit 1), such as myocardial infarction, uncontrolled angina/coronary artery disease, significant ventricular arrhythmias and heart failure (New York Heart Association class III/IV).
- •5. Participant with chronic diseases requiring continuous use (internal, injection, etc.) of systemic corticosteroids and/or immunosuppressive agents.
- •6. Participant with a malignant tumor (recurrence-free period less than 5 years).
- •7. Participant with serious infections.
- •8. Participant with serious liver disorder.
- •9. Participant with drug addiction, alcoholism, or unstable psychiatric illness.
- •10. Participant who is using insulin preparations.
- •11. Participant planning to be hospitalized or undergo surgery during the study period.
- •12. Participant who has previously been assigned to study treatment in this study.
- •13. Participant has received some study treatment (including the follow-up period) within 12 weeks (84 days) prior to visit 1 (including the day of visit 1) or within 5 times the half-life of the treatment at Week 12 (84 days) prior to visit 1.
- •14. Participant who has used a mobile app for the purpose of managing or assisting in the management of diabetes within 12 weeks (84 days) prior to visit 1 (including the day of visit 1) and has been determined that such past use affects the efficacy evaluation of this study.
- •15. Participant with a difference of >1.0 percentage between the highest and lowest HbA1c values (in-hospital measurement) measured within 12 weeks (84 days) prior to visit 1 (including the day of visit 1).
- •16. Participant with sitting systolic blood pressure (SBP) at rest >180 mmHg or sitting diastolic blood pressure (DBP) at rest >110 mmHg at least either visit 1 or Visit 2, or participant with sitting SBP at rest >160 mmHg or sitting DBP at rest >100 mmHg at both visit 1 and visit 2.
- •17. Participant with stage 3 or later diabetic nephropathy (estimated glomerular filtration rate [eGFR] less than 30 mL/min/1.73m^2 or urinary albumin of 300 mg/gCre or more; both values from the central lab measurement at visit 1).
- •18. Participant who owns and uses a smartphone device that may not properly display BAP0527 application, or participant who plans to replace his/her smartphone to such a device during the period from the time of informed consent to the end of the treatment period.
- •19. Participant is an employee of Astellas Group, Welldoc, Inc., Roche DC Japan K.K., relevant CROs or participating medical institutions.
- •20. Participant has any condition makes the participant unsuitable for study participation.
研究者
相似试验
进行中（未招募）
1 期
A study to test the efficacy and safety of padsevonil as treatment of focal-onset seizures in adult subjects with drug-resistant epilepsyFocal-Onset SeizuresMedDRA version: 21.1Level: LLTClassification code 10065337Term: Focal epilepsySystem Organ Class: 100000004852EUCTR2018-002303-33-BECB Biopharma SR625
招募中
3 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate CancerNon-Metastatic Castration-Resistant Prostate Cancernon-spread Castration-Resistant Prostate Cancer10036958NL-OMON54510Aragon Pharmaceuticals, Inc.35
进行中（未招募）
1 期
A study to look at the effect and how safe drug VIS649 is in patients with kidney diseaseEUCTR2019-002531-29-GBVisterra, Inc.144
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2.5 mg Saxagliptin, PO, BID, in Combination with Metformin in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin, Alone.Type 2 Diabetes MellitusEUCTR2009-010224-25-HUBristol-Myers Squibb International Corporation152
进行中（未招募）
不适用
Research study testing the safety and tolerability of the investigationaldrug, BMS-708163, compared to placebo (inactive substance) in subjectswith prodromal Alzheimer's DiseaseALZHEIMER DISEASEMedDRA version: 15.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2009-010067-16-SEBristol-Myers Squibb International Corporation540